Recent studies highlight BDMC’sstronger NF-κB inhibition compared to CUR and DMC in cell models,along with its ability to target pathways associated with inflammatorybowel disease (IBD) in DSS-induced colitis mice, reflected by lowerdisease activity scores and reduced inflammation. Here, NFKB1 is linked to irritable bowel syndrome.